UK-based healthtech company Nul, which develops a supported alcohol reduction platform combining clinical care and prescription medication, has raised $1 million in seed funding from dmg ventures and BYVP, with participation from a group of angel investors.
- Established in 2024 by Matus Maar, Nul develops a telehealth platform for alcohol reduction. The platform integrates clinical care, prescription medication, and digital treatment pathways to help individuals reduce their alcohol consumption without requiring complete abstinence.
- Nul’s programme is based on The Sinclair Method and uses naltrexone, a medication that targets the brain’s reward pathways to reduce alcohol cravings. After an initial online consultation, a clinician assesses suitability and prescribes a personalised treatment plan, which can include structured digital guidance and optional therapy such as Internal Family Systems (IFS) and polyvagal therapy.
- The service is delivered remotely via a subscription model, providing ongoing clinical oversight, access to digital resources, and regular support from qualified clinicians and therapists. Nul partners with healthcare providers such as Blueco Healthcare for clinical services and Thriva for at-home liver function testing to monitor progress.
- The company launched a UK test phase in summer 2025 and onboarded more than 120 paying customers, achieving an annualised revenue run rate of over £300,000 within its first months, driven largely by organic demand and word-of-mouth.
"Telehealth and online pharmacy platforms have transformed categories like weight loss and mental health, yet alcohol has been left behind despite the scale of the problem. NUL is about making evidence-based treatment accessible, discreet and compatible with real life," explains Matus Maar, founder and CEO of Nul.
Details of the deal
- The fresh $1 million capital will enable Nul to execute its full UK commercial launch while expanding its clinical and product teams to support more users. The funding will also help scale customer acquisition efforts and lay the groundwork for future international growth, including entry into the US market. Alongside this institutional investment, Nul plans to launch a crowdfunding campaign on Republic Europe to involve retail investors in its next phase of expansion.
